<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ANTIPSYCHOTIC DRUGS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>ANTIPSYCHOTIC DRUGS</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">







      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Neuroleptic malignant syndrome&#8212;discontinue (potentially fatal),
              </p>
              <p>
                <strong>veryRare:</strong> Precipitation of angle-closure glaucoma,
              </p>
              <p>
                <strong>notKnown:</strong> Agitation, agranulocytosis, akathisia, antimuscarinic symptoms, apathy, blood dyscrasias, blurred vision, cardiovascular side-effects, confusion, constipation, contact sensitisation, convulsions, corneal and lens opacities, diabetes, difficulty with micturition, dizziness, drowsiness, dry mouth, dystonia, excitement, extrapyramidal symptoms, gastro-intestinal disturbances, headache, hyperglycaemia, hyperprolactineamia, hypotension (dose related), insomnia, interference with temperature regulation (dose related), jaundice (including cholestatic), leucopenia, nasal congestion, parkinsonian symptoms, photosensitisation, purplish pigmentation of the conjunctiva, purplish pigmentation of the cornea, purplish pigmentation of the retina, purplish pigmentation of the skin, rashes, sexual dysfunction, tardive dyskinesia, venous thromboembolism, weight gain,
              </p>
        
        
        
            <section class="overdosageInformation">
              <p>Phenothiazines cause less depression of consciousness and respiration than other sedatives. Hypotension, hypothermia, sinus tachycardia, and arrhythmias may complicate poisoning. Dystonic reactions can occur with therapeutic doses (particularly with prochlorperazine and trifluoperazine), and convulsions may occur in severe cases. Arrhythmias may respond to correction of hypoxia, acidosis, and other biochemical abnormalities, but specialist advice should be sought if arrhythmias result from a prolonged QT interval; the use of some anti-arrhythmic drugs can worsen such arrhythmias. Dystonic reactions are rapidly abolished by injection of drugs such as procyclidine or diazepam (emulsion preferred).</p>
            </section>
            <section class="overdosageInformation">
              <p>Features of poisoning by second-generation antipsychotic drugs include drowsiness, convulsions, extrapyramidal symptoms, hypotension, and ECG abnormalities (including prolongation of the QT interval). Management is supportive. Activated charcoal can be given within 1 hour of ingesting a significant quantity of a second-generation antipsychotic drug.</p>
            </section>
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>As photosensitisation may occur with higher dosages, patients should avoid direct sunlight.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Blood dyscrasias
          </li>
          <li>
            cardiovascular disease
          </li>
          <li>
            conditions predisposing to seizures
          </li>
          <li>
            depression
          </li>
          <li>
            epilepsy
          </li>
          <li>
            history of jaundice
          </li>
          <li>
            myasthenia gravis
          </li>
          <li>
            Parkinson&#8217;s disease (may be exacerbated)
          </li>
          <li>
            photosensitisation (may occur with higher dosages)
          </li>
          <li>
            prostatic hypertrophy
          </li>
          <li>
            severe respiratory disease
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
        <ul>
          <li>
            <p>An ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease, or if the patient is being admitted as an inpatient.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>It is advisable to monitor prolactin concentration at the start of therapy, at 6 months, and then yearly. Patients taking antipsychotic drugs not normally associated with symptomatic hyperprolactinaemia should be considered for prolactin monitoring if they show symptoms of hyperprolactinaemia (such as breast enlargement and galactorrhoea).</p><p>Patients with schizophrenia should have physical health monitoring (including cardiovascular disease risk assessment) at least once per year.</p>
            </section>
      </section>











      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of ANTIPSYCHOTIC DRUGS</h2>

          <ul>
            <li><a href="../drug/PHP2211.html">BENPERIDOL</a></li>
            <li><a href="../drug/PHP2213.html">CHLORPROMAZINE HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP2220.html">FLUPENTIXOL</a></li>
            <li><a href="../drug/PHP2226.html">HALOPERIDOL</a></li>
            <li><a href="../drug/PHP2234.html">LEVOMEPROMAZINE</a></li>
            <li><a href="../drug/PHP2238.html">PERICYAZINE</a></li>
            <li><a href="../drug/PHP2240.html">PERPHENAZINE</a></li>
            <li><a href="../drug/PHP2244.html">PIMOZIDE</a></li>
            <li><a href="../drug/PHP2247.html">PROCHLORPERAZINE</a></li>
            <li><a href="../drug/PHP2251.html">PROMAZINE HYDROCHLORIDE</a></li>
            <li><a href="../drug/PHP2253.html">SULPIRIDE</a></li>
            <li><a href="../drug/PHP2258.html">TRIFLUOPERAZINE</a></li>
            <li><a href="../drug/PHP2261.html">ZUCLOPENTHIXOL</a></li>
            <li><a href="../drug/PHP2264.html">ZUCLOPENTHIXOL ACETATE</a></li>
            <li><a href="../drug/PHP2268.html">AMISULPRIDE</a></li>
            <li><a href="../drug/PHP2271.html">ARIPIPRAZOLE</a></li>
            <li><a href="../drug/PHP2273.html">CLOZAPINE</a></li>
            <li><a href="../drug/PHP2277.html">OLANZAPINE</a></li>
            <li><a href="../drug/PHP2280.html">PALIPERIDONE</a></li>
            <li><a href="../drug/PHP2284.html">QUETIAPINE</a></li>
            <li><a href="../drug/PHP2288.html">RISPERIDONE</a></li>
            <li><a href="../drug/PHP2303.html">FLUPENTIXOL DECANOATE</a></li>
            <li><a href="../drug/PHP2307.html">FLUPHENAZINE DECANOATE</a></li>
            <li><a href="../drug/PHP2313.html">OLANZAPINE EMBONATE</a></li>
            <li><a href="../drug/PHP2317.html">PIPOTIAZINE PALMITATE</a></li>
            <li><a href="../drug/PHP2321.html">ZUCLOPENTHIXOL DECANOATE</a></li>
            <li><a href="../drug/PHP2327.html">ASENAPINE</a></li>
            <li><a href="../drug/PHP80616.html">HALOPERIDOL DECANOATE</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
